
Medical Oncologist, Cancer Researcher, Drug Developer, ex-@MDAndersonNews, Chief Medical Officer @MonteRosaTx. Views are mine.
Boston, MA
Joined August 2017
- Tweets1.2K
- Following757
- Followers1.3K
- Likes2.5K
Just in case anyone is interested in joining 🦋. I have been pleasantly surprised. Lot of #MedTwitter crowd migrated there.
After X owner Elon Musk helped Donald Trump successfully run for office, some X users are jumping ship for the decentralized Twitter clone Bluesky. wapo.st/48NDyCk
3
638
Filip Janku retweeted
ICYMI: Our team was on the ground for this week’s 7th #TPD and Induced Proximity Summit.
View our presentations to learn more about Monte Rosa’s work on CDK2 and Cyclin E1 #moleculargluedegraders, as well as our programs in GSPT1 and VAV1.
bit.ly/3ChLkrJ
Filip Janku retweeted
Attending the 7th #TPD and Induced Proximity Summit?
Nina Ilic-Widlund, Director of Oncology Biology, shares how we’re accelerating the rational discovery and design of #moleculargluedegraders, including CDK2 and Cyclin E1 #MGDs. Join us to learn more!
bit.ly/40nWpS9
Filip Janku retweeted
Interested in Monte Rosa’s molecular glue degraders for #oncology and #autoimmune diseases?
Chief Medical Officer @FilipJankuMD presents on how we’re taking #MGDs from the bench to the clinic at the 7th #TPD and Induced Proximity Summit.
bit.ly/40nWpS9
Filip Janku retweeted
I’m happy to share that Novartis and @MonteRosaTx have announced an exclusive global development and commercialization license agreement to advance molecular glue degraders. ir.monterosatx.com/news-rele…
We believe VAV1 molecular glue degraders such as MRT-6160 have the potential for a differentiated therapeutic profile in T-cell, T/B-cell, and Th17-mediated indications. It’s our hope this agreement moves us a step closer to bringing MRT-6160 to patients worldwide.
Today we announced a global license agreement with @Novartis to advance VAV1-directed MGDs. This agreement is expected to accelerate clinical development of MRT-6160 and explore its therapeutic potential across multiple indications.
Learn more: bit.ly/3YDsioB
Filip Janku retweeted
Deeply humbled to receive the 2024 Pulitzer Prize for my @washingtonpost columns written from prison. I dedicate it to all journalists imprisoned in Russia — and the monetary part will go the 30 October Foundation that helps the families of Russian political prisoners.
Filip Janku retweeted
The piece focuses on how companies including Monte Rosa are pushing the boundaries of the druggable target space with molecular glue degraders for GSPT1, VAV1, and other novel targets.
Filip Janku retweeted
Thanks to Asher Mullard and @NatRevDrugDisc for the great article and interview with our CEO Markus Warmuth and our CSO Sharon Townson. nature.com/articles/d41573-0…
Focusing on undruggable targets isn’t just an intellectual pursuit but it’s also incredibly important for patients. It’s our great hope that by striking out in new directions, we can provide much-needed new therapeutic options for patients. I am very proud of the team @MonteRosaTx for leading the way in this pursuit of new #MolecularGlueDegraders.
Replying to @MonteRosaTx
Sharon Townson, our Chief Scientific Officer, and John Castle, Chief Data and Information Officer, comment on the key takeaways. Read the publication here: bit.ly/3YmFEWk
Special thanks to first authors Georg Petzold and Pablo Gainza!
3
552
Filip Janku retweeted
Sharon Townson, our Chief Scientific Officer, and John Castle, Chief Data and Information Officer, comment on the key takeaways. Read the publication here: bit.ly/3YmFEWk
Special thanks to first authors Georg Petzold and Pablo Gainza!
Filip Janku retweeted
At Monte Rosa, we have taken the bold and differentiating approach of focusing the development of our #moleculargluedegraders (MGDs) on previously undruggable targets. Today we published a paper demonstrating how we do it in BioRxiv.org.
Filip Janku retweeted
🦄UPDATE on qualifier registration for the 129th Boston Marathon presented by @BankofAmerica🦄
24,069 qualifiers who ran 6:51 or faster than their qualifying standard have been accepted into April’s race!💙💛
Email notices have begun being issued.
🔗 bstnmar.org/25BMAcceptances
Welcome to @zrh_airport 🥲🥲🥲. Lucky me that I am not connecting
2
2
167
Filip Janku retweeted
Khin Naing Foundation USA will be volunteering at @HoustonFoodBank in memory of Dr. Jing Gong @JingGong14 on 10/13/24. Join us at knfoundation-usa.com/dr-jing… as we honor Dr. Gong's legacy by lending a helping hand to those in need. #KhinNaingFoundationUSA
Filip Janku retweeted
VAV1 as a putative therapeutic target in autoimmune and chronic inflammatory diseases dlvr.it/TBg66r
Filip Janku retweeted
We’re changing the game for #ColorectalCancer screening w/ the FDA approval of Shield, our blood test for people age 45+ at average risk. With Shield, we aim to get more people tested & catch more cancers early, when they’re most treatable.
Read more: bit.ly/3WnfKzi
Filip Janku retweeted
VAV1 as a putative therapeutic target in autoimmune and chronic inflammatory diseases dlvr.it/TB4WV7 #immunology




















